Clinical Trials on Childhood Diffuse Large Cell Lymphoma

Total 7237 results

University Hospital Southampton NHS Foundation...
Janssen-Cilag Ltd.

Completed

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (REMoDL-B)

Lymphoma, Large B-Cell, Diffuse

United Kingdom, Switzerland
Wenqi Jiang

Unknown

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
University College, London

Completed

Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Lymphoma

United Kingdom
Celltrion

Terminated

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial (Triad-DLBCL)

Diffuse Large B-Cell Lymphoma

Korea, Republic of
Favrille

Suspended

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Hoosier Cancer Research Network
Eli Lilly and Company; Walther Cancer Institute

Terminated

Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma, B-Cell

United States
British Columbia Cancer Agency
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

Canada, United States
New York Medical College

Completed

Treatment for Advanced B-Cell Lymphoma (REBOOT)

Diffuse Large Cell Lymphoma | Burkitt's Lymphoma | High Grade B-cell Lymphoma

United States
Ruijin Hospital

Not yet recruiting

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Richter Syndrome | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Massachusetts General Hospital
Dana-Farber Cancer Institute; Brigham and Women's Hospital; Genzyme, a Sanofi...

Completed

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | Anaplastic Large-cell Lymphoma | Low Grade B-cell Lymphoma, Not Otherwise Specified

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Follicular Lymphoma | B Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Plasma Cell Neoplasm | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Primary Cutaneous Follicle Centre Lymphoma

China
Sutro Biopharma, Inc.

Completed

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Indolent Lymphoma | B Cells--Tumors

United States
Patrick C. Johnson, MD
AstraZeneca

Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult... and other conditions

United States, Germany, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Transformed... and other conditions

United States
Case Comprehensive Cancer Center

Completed

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Tandem Auto-Allo Transplant for Lymphoma

Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Low-Grade | Diffuse, Large B-Cell, Lymphoma | T-Cell Lymphoma | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Experimental
Hoffmann-La Roche

Terminated

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Diffuse Large B-Cell Lymphoma

Romania
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Bulgaria, Belgium, Hungary, Ukraine, Italy, Poland, Switzerland
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.

Completed

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Non-Hodgkin's Lymphoma

United States
Eli Lilly and Company

Completed

A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Non-Hodgkin's Lymphoma

United States
Inje University

Unknown

BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)

Non Hodgkin's Lymphoma

Korea, Republic of
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Follicular Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
Gilead Sciences

Withdrawn

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Diffuse Large B-Cell Lymphoma | Mediastinal B-cell Lymphoma

Italy, Spain, France, Poland
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)

Diffuse Large B-Cell Lymphoma | IPI≥2

Italy
Case Comprehensive Cancer Center

Terminated

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Ajou University School of Medicine

Unknown

Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma | Neutropenia, Febrile

Korea, Republic of
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab

Lymphoma
Roswell Park Cancer Institute
Ortho Biotech, Inc.

Terminated

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Lymphoma

United States
Gruppo Italiano Multiregionale per lo studio dei...
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
Mayo Clinic
National Cancer Institute (NCI)

Completed

Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma

Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Lymphoma
Samsung Medical Center

Completed

Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma

Diffuse Large B-cell Lymphoma

Korea, Republic of
New York Medical College

Completed

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia (MITCL)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Myelogenous Leukemia | Diffuse Large B-cell Lymphoma | Burkitt Lymphoma/Leukemia

United States
Jennifer Woyach
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
Genentech, Inc.

Completed

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, Canada, France, Italy, Germany, Netherlands
University of Pennsylvania

Completed

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

United States
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States

Clinical Trials on Childhood Diffuse Large Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations